Prior to partnering with GTCR, Mr. Hance served as Chief Executive Officer of Creganna Medical, a leading supplier of contract manufacturing services for medical devices, where he significantly grew the business via acquisitions and organic growth before completing a successful sale of the company in 2016 to TE Connectivity. Going forward, the existing Biocoat management team, led by CEO Jim Moran, will continue in their existing roles executing on Biocoat's growth initiatives in partnership with GTCR. About GTCRFounded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications industries. To explore GTCRs full profile, request access. real person. Evercore served as financial advisor to GTCR. Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. Founded in 1991 and headquartered in Horsham, Pennsylvania, Biocoat is a leading medical device contract manufacturing organization ("CMO"), specializing in custom, biocompatible hydrophilic coatings for interventional medical devices. Learn more at www.biocoat.com. CHICAGO & NEW YORK--(BUSINESS WIRE)--GTCR LLC and Blackstone (NYSE:BX) today jointly announced a new partnership in which funds managed by Blackstones GP Stakes business will acquire a minority ownership interest in GTCR. The Company provides anatomic pathology, digital pathology, molecular diagnostic, and clinical testing services to physician groups and hospital systems across the Southeast and Midwest. Finally, we have a talented group of investment professionals and staff, and we are dedicated to providing our team with the most opportunity for professional growth and impact, while working in a collaborative and inclusive environment. The Company's capabilities include developing and supplying customized coatings formulations, performing coatings application services, and offering coatings equipment solutions. The terms of the transaction were not disclosed. Mr. Hance also spent more than 20 years in senior leadership roles at Abbott Laboratories, culminating with his role as President of Abbott's Vascular division, building it into a global leader in interventional cardiology with more than $3 billion in revenues.